Abstract:Systemic sclerosis is an autoimmune disease leading to vasculopathy and fibrosis of skin and internal organs. Despite likely shared pathogenic mechanisms, the patterns of skin and lung fibrosis differ. Pathogenesis of interstitial lung disease, a major cause of death in systemic sclerosis, reflects the intrinsic disease pathobiology and is associated with distinct clinical phenotypes and laboratory characteristics. The commonest histological pattern of systemic sclerosis–interstitial lung disease is non-specific interstitial pneumonia. Systemic sclerosis–interstitial lung disease pathogenesis involves multiple components, including susceptibility and triggering factors, which could be genetic or environmental. The process is amplified likely through ongoing inflammation and the link between inflammatory activity and fibrosis with IL6 emerging as a key mediator. The disease is driven by epithelial injury, reflected by markers in the serum, such as surfactant proteins and KL-6. In addition, mediators that are produced by epithelial cells and that regulate inflammatory cell trafficking may be important, especially CCL2. Other factors, such as CXCL4 and CCL18, point towards immune-mediated damage or injury response. Monocytes and alternatively activated macrophages appear to be important. Transforming growth factor beta appears central to pathogenesis and regulates epithelial repair and fibroblast activation. Understanding pathogenesis may help to unravel the stages of systemic sclerosis–interstitial lung disease, risks of progression and determinants of outcome. With this article, we set out to review the multiple factors, including genetic, environmental, cellular and molecular, that may be involved in the pathogenesis of systemic sclerosis–interstitial lung disease and the mechanisms leading to sustained fibrosis. We propose a model for the pathogenesis of systemic sclerosis–interstitial lung disease, based on the available literature.

Systemic sclerosis associated respiratory involvement: Scopus-based analysis of articles in 2013–2022

Lung involvement in systemic sclerosis

The 'whole landscape' of research on systemic sclerosis over the past 73 years

Interstitial Lung Disease Associated with Systemic Sclerosis

Interstitial lung disease in systemic sclerosis: challenges in early diagnosis and management

Heterogeneity of determining disease severity, clinical course and outcomes in systemic sclerosis-associated interstitial lung disease: a systematic literature review

Diagnosis and Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease: Current Status and Advances

Interstitial lung disease in Systemic sclerosis: insights into pathogenesis and evolving therapies

The need for a holistic approach for SSc-ILD - achievements and ambiguity in a devastating disease

Predictors of progression in systemic sclerosis patients with interstitial lung disease

Pathogenesis of interstitial lung disease in systemic sclerosis

The interplay between rheumatic diseases and pulmonary health

Expert consensus on the management of systemic sclerosis-associated interstitial lung disease

Heart involvement in patients with systemic sclerosis-what have we learned about it in the last 5 years

Pathogenesis of systemic sclerosis associated interstitial lung disease

[Update on systemic sclerosis]

Systemic sclerosis: one year in review 2024

Potential Role of JAK Inhibitors in the Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease: A Narrative Review from Pathogenesis to Real-Life Data

Systemic scleroderma: Review and updated approach and case description to addressing pulmonary arterial hypertension and idiopathic pulmonary fibrosis: A dual challenge in treatment

Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)